Lisata Therapeutics has been granted a new patent for certepetide, its lead drug candidate for solid tumor cancers. The patent covers the drug’s unique chemical structure, manufacturing process, and treatment application. Certepetide is an investigational peptide drug designed to improve anti-cancer therapy delivery into tumors.

The new patent is a significant milestone for Lisata, providing IP protection for the drug for the next two decades. This strengthens the company’s position in negotiations with potential partners and enhances shareholder value. David J. Mazzo, President and CEO of Lisata, highlighted the importance of this patent in driving sustained growth and value creation for the company.

For more information, visit HealthcareEdge. Lisata Therapeutics also recently reported trial results for its pancreatic cancer treatment. Stay updated on healthcare news by registering for their weekly newsletter. Contact Exec Edge for further inquiries or information. Follow Exec Edge on LinkedIn for the latest updates and news.

Read more at Yahoo Finance: Lisata Secures New Composition of Matter Patent for Certepetide